製品名
Anti-IDO Antibody, clone 1F8.2, clone 1F8.2, from mouse
biological source
mouse
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
1F8.2, monoclonal
species reactivity
human
technique(s)
immunohistochemistry: suitable
western blot: suitable
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... IDO1(3620)
Analysis Note
Control
HeLa cell lysate treated with interferon gamma.
HeLa cell lysate treated with interferon gamma.
Evaluated by Western Blot in HeLa cell lysate.
Western Blot Analysis: 0.1 µg/mL dilution of this antibody detected IDO on 15 µg of HeLa cell lysate.
Western Blot Analysis: 0.1 µg/mL dilution of this antibody detected IDO on 15 µg of HeLa cell lysate.
Application
Anti-IDO Antibody, clone 1F8.2 is an antibody against IDO for use in WB, IH.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Oxidative Stress
Oxidative Stress
Biochem/physiol Actions
This antibody recognizes IDO.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
Approx. 45 kDa
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that is responsible for converting tryptophan to kynurenines. IDO is expressed by a wide variety of tissues and IDO can be upregulated by interferon gamma. IDO modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in the suppression of the immune response. IDO may be involved in the
suppression of the immune response to tumours and blocking the IDO pathway may be a potential target for immunotherapy.
suppression of the immune response to tumours and blocking the IDO pathway may be a potential target for immunotherapy.
Immunogen
GST-tagged recombinant protein of full-length human IDO.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Format: Purified
Mouse monoclonal in buffer containing 0.1 M Tris-glycine, pH 7.4, 150 mM NaCl and 0.05% sodium azide.
Protein G Purified
Preparation Note
Maintain refrigerated at 2-8°C for 1 year from date of receipt.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Maria A Papadaki et al.
Cancers, 12(6) (2020-06-18)
The current study aimed at the optimization of circulating tumor cell (CTC) enrichment for downstream protein expression analyses in non-small cell lung cancer (NSCLC) to serve as a tool for the investigation of immune checkpoints in real time. Different enrichment
A Marijne Heeren et al.
Frontiers in immunology, 9, 1598-1598 (2018-07-28)
The indoleamine 2,3-dioxygenase (IDO) enzyme can act as an immunoregulator by inhibiting T cell function via the degradation of the essential amino acid tryptophan (trp) into kynurenine (kyn) and its derivates. The kyn/trp ratio in serum is a prognostic factor
Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome.
Gorris, et al.
Journal for Immunotherapy of Cancer, 10 (2022)
Tamara Vorobjova et al.
World journal of gastroenterology, 21(2), 439-452 (2015-01-17)
To investigate the densities of dendritic cells (DCs) and FOXP3(+) regulatory T cells (Tregs) and their interrelations in the small bowel mucosa in untreated celiac disease (CD) patients with and without type 1 diabetes (T1D). Seventy-four patients (45 female, 29
Lieke L van der Woude et al.
Journal for immunotherapy of cancer, 10(10) (2022-10-18)
Immunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do not respond to this treatment, therefore combination strategies are being explored to increase clinical benefit. The PEMBRO-RT trial
グローバルトレードアイテム番号
| カタログ番号 | GTIN |
|---|---|
| MAB10009 | 04053252667589 |
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)